Bengaluru: In the single largest deal within India’s life sciences real estate sector, Rx Propellant, the country’s leading Life sciences infrastructure platform, has leased a 1.3 lakh square feet of R&D facility- Nextopolis to GV Research Plat form (GVRP), an integrated contract research research organization (CRO) in the biopharma industry

The deal, sealed by Rx Propellant for ₹162 crore will allow NABLac credited research organization an occupancy for 10 years.

“Life Sciences is an immensely promising industry in India and this deal is a testimony to the rising demand of premier labspaces, tallormade to support diverse operational needs. Nextopolis, officially launched in 2022, was designed and built as a one-of-its-kind facility for blomedical research and pilot manufacturing,” said Milind Ravi,chief executive officer, Rx Propellant.

Nextopolis, located in Hyderabad’s Genome Valley, is developed by Modi Properties and will enable GVRP to expand its service portfolio and consolldate all complementary offerings under one roof.

“GVRP distinguishes itself in the market by seam lessly integrating research models and preclinical testing capabilities. Aligned with our commitment to accelerating innovation, our partnership with Envigo RMS LLC, alongside our state-of-the-art rese- arch facility meeting international standards like OECD-GLP and AA- ALAC International, is geared to- wards delivering unparalleled sup- port for advancing ground-brea- king research in the field of life sciences,” said Kalyan Korisapati, chief executive officer, GV Rese arch Platform.